
Last updated: 2026-09-06 11:52:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Immunovant, Inc. (IMVT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $39.27, with a market capitalization of $8.11B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.58 to $45.42. This page covers its latest market performance, valuation, price trends and company information.
$8.11B | |
$39.44 | |
$53.75 | |
$3.15 | |
$39.12 | |
543.58K | |
1.26M | |
-- | |
$45.42 | |
$14.58 | |
-- | |
-- |
Immunovant, Inc. (IMVT) last closed at $39.12 as of 2026-09-04 23:31:00, unchanged from the previous close of $39.12.
During the latest regular trading session, IMVT traded between $3.15 and $53.75, with a volume of 543.58K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Immunovant, Inc. (IMVT) moved from $43.82 to $39.27, representing a decline of 10.38% ($4.55).
The stock traded between $38.61 and $43.95 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.18 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 80.1%
IMVT is currently trading at $39.27, placing it 80.1% of the way from its 52-week low of $14.58 to its 52-week high of $45.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 315 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunovant, Inc. (IMVT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.